BioMarin's VOXZOGO® Demonstrates Early Treatment Benefits for Children with Achondroplasia

BioMarin’s VOXZOGO® Shows Promising Results in Early Treatment for Achondroplasia

BioMarin Pharmaceutical Inc. announces encouraging findings from its studies on VOXZOGO® (vosoritide), which reaffirm the advantages of early intervention for children diagnosed with achondroplasia. Achondroplasia, the most common form of dwarfism, has historically presented challenges in managing growth and associated comorbidities. The data reveal that initiation of treatment before the age of two results in statistically significant improvements in various health outcomes, including body proportionality, arm span, and body mass index (BMI). With more than 10,000 patient-years of data, VOXZOGO stands out as the only approved therapy for this condition from birth, which is further validated by extensive clinical evidence.

The findings highlight that children who begin treatment with VOXZOGO before the age of two exhibit a least squares mean difference of −0.33 (p=0.0005) in body proportionality after one year compared to untreated counterparts, and this gap widens to −0.53 (p<0.0001) by the fourth year. For those starting treatment before six months, the differences in proportionality are also pronounced, with a yearly measure of −0.10 (p=0.042) and −0.23 (p=0.0003) noted by year four. These substantial changes emphasize the drug's effectiveness in enhancing growth outcomes, particularly for the youngest patients who are most likely to experience continued improvements in height and body proportion stability as they develop.

Michael Hughes from Little People of America praises these results as pivotal, underlining BioMarin's dedication to exploring the comprehensive benefits of early treatment. By documenting notable enhancements in arm-to-height ratios and positive effects on BMI, BioMarin reaffirms its commitment to understanding the broader impacts of VOXZOGO. This aligns with the stakeholders’ concerns regarding not only the physical aspects of achondroplasia but also the holistic well-being of children experiencing this condition.

In addition to the clinical developments surrounding VOXZOGO, the upcoming presentation of these results at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Baltimore indicates a proactive approach in disseminating critical research findings. The emphasis on presenting robust patient data solidifies BioMarin's position as a leader in genetic therapies and highlights its ongoing commitment to support children with achondroplasia and their families.